BofA Securities on Abbott Labs (ABT): 'durable revenue growth at the high end of medtech and double-digit EPS growth'
Tweet Send to a Friend
BofA Securities analyst Travis Steed reiterated a Buy rating and $150.00 price target on Abbott Labs (NYSE: ABT).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
